Dr. Israel Crespo, MD

Dr. Crespo practices at Tampa Bay Endoscopy Center in Tampa, Florida.

Dr. Crespo's NPI, 1942302880, was assigned on September 1, 2006. Dr. Crespo graduated from University of Puerto Rico, Medical Sciences Campus in 1985. Dr. Crespo holds Florida license ME0067924.

Dr. Crespo's primary practice is Tampa Bay Endoscopy Center, at 4809 N Armenia Ave, Ste 100, Tampa, FL 33603. The practice phone is (813) 872-9310.

Dr. Crespo's primary practice is Tampa Bay Endoscopy Center in Tampa, Florida. Dr. Crespo is also affiliated with AdventHealth Carrollwood. Dmand AI also links Dr. Crespo to 1 more hospital and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Crespo practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Crespo's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Crespo is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Crespo's licenses on file in 2 states: Florida and Texas.

Dmand AI lists acid reflux, acute gastroduodenitis, chronic indigestion, chronic inflammatory bowel disease (IBD), colonoscopy, gastroduodenitis, gastrointestinal bleeding and hepatitis c among the conditions Dr. Crespo treats.

CMS data shows 395 Medicare services from Dr. Crespo across 10 procedure codes in 2024, for 206 Medicare patients. Medicare paid $37,545 for them.

CMS counts 206 Medicare patients who saw Dr. Crespo in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Crespo's median patient age at 68, with 60% women.

In 2024, Dr. Crespo wrote 3,257 Medicare Part D claims for 1,033 patients. 71% of them were for generic drugs. CMS names the drug for 2,951 of them, across 41 drugs with 11 or more claims each, at $3,035,487 in total drug cost. In 2023, CMS named 2,974 claims across 44 drugs.

Dr. Crespo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 498 procedures of colonoscopy by Dr. Crespo, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Crespo in 2013. Dr. Crespo's most frequent co-authors are Tarek I. Hassanein, MD, Robert Hindes, MD and Kris V. Kowdley, MD.

Dmand AI links Dr. Crespo to 5 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Crohn Disease, Inflammatory Bowel Diseases and Constipation. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Crespo that name 3 trials.

CMS Open Payments shows 1,750 general payments to Dr. Crespo from 63 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 68% of the total. Abbvie Inc. paid the most, $24,431. It also lists 6 research payments totaling $6,366 from 2019 to 2022, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Crespo, most recently CMS Stage 1 2012 in 2011.

Dr. Crespo graduated from University of Puerto Rico, Medical Sciences Campus in 1985. Dr. Crespo is a member of ACG.

Dr. Crespo is in network with 5 carriers, including Elevance, Aetna and Humana. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.